Skip to content

US · SLXN · BIOTECHNOLOGY

Silexion Therapeutics Ltd. (SLXN) intrinsic value and stock valuation

$1.31as of 2026-11-21 · Mkt cap 783.52K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Silexion Therapeutics Ltd. DCF and intrinsic value

InvestorsCraft values SLXN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SLXN’s statements →

Silexion Therapeutics Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ramat Gan 5250606 silexion.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-11.91M
20202025
Free cash flow
-$-10.83M
20202025
Total equity
$2.6M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income$11.6M-$-12.57M-$-4.68M-$-3.86M-$-940K
Net income-$-11.91M-$-16.44M-$-4.94M-$-3.21M-$-760K
EPSd-$-91.62M-$-26.52M-$-44.91M-$-1.92M-$-460.61K
Operating cash flow-$-10.82M-$-8.4M-$-4.53M-$-3.33M-$-1.41M
Capital expenditure-$-10K-$-20K-$-10K-$-40K-$0.00
Free cash flow-$-10.83M-$-8.42M-$-4.54M-$-3.38M-$-1.41M
Total assets$7.21M$2.86M$5.26M$9.33M$115.4M
Total debt$470K$4.49M$170K$270K$0.00
Net debt-$-5.52M$3.3M-$-4.42M-$-7.99M-$-40K
Total equity$2.6M-$-3.99M-$-12.06M-$-7.08M$114.9M
Cash and short-term investments$5.99M$1.19M$4.59M$8.26M$40K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$7.14M$5.82M$3.71M$3.23M$0.00
Selling, general and administrative expenses$4.48M$6.73M$930K$580K$940K
Other expenses-$-23.25M$30K$40K$60K$0.00
Operating expenses-$-11.63M$12.6M$4.68M$3.86M$940K
Cost and expenses-$-11.63M$12.6M$4.68M$3.86M$940K
Interest income$140K$0.00$150K$110K$10K
Interest expense$10K$50K$10K$90K$0.00
Depreciation and amortization$10K$30K$40K$60K$0.00
Ebitda-$-11.88M-$-16.48M-$-5.02M-$-3.32M-$-760K
Operating income$11.6M-$-12.57M-$-4.68M-$-3.86M-$-940K
Total other income/expenses, net-$-23.54M-$-3.94M-$-400K$400K$190K
Income before tax-$-11.91M-$-16.51M-$-5.08M-$-3.46M-$-760K
Income tax expense$0.00$10K$30K$20K$0.00
Net income-$-11.91M-$-16.44M-$-4.94M-$-3.21M-$-760K
Weighted average shares outstanding$130K$620K$110K$1.67M$1.65M
Weighted average diluted shares outstanding$130K$620K$110K$1.67M$1.65M
Balance sheet
20252024202320222021
Cash and short-term investments$5.99M$1.19M$4.59M$8.26M$40K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.64M$2.25M$4.98M$8.84M$410K
Property, plant and equipment, net$440K$560K$250K$460K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$60K$0.00$0.00$0.00$115M
Total non-current assets$580K$610K$280K$490K$115M
Total assets$7.21M$2.86M$5.26M$9.33M$115.4M
Accounts payable$790K$930K$320K$240K$0.00
Short-term debt$180K$1.16M$110K$120K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.76M$3.52M$2.2M$1.61M$350K
Long-term debt$290K$3.33M$60K$160K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.85M$3.33M$15.1M$14.8M$160K
Capital lease obligations$0.00$530K$170K$270K$0.00
Total liabilities$4.61M$6.85M$17.3M$16.4M$510K
Common stock$40K$0.00$0.00$0.00$115M
Retained earnings-$-55.17M-$-43.25M-$-26.81M-$-21.87M-$-950K
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.6M-$-3.99M-$-12.06M-$-7.08M$114.9M
Total investments$60K$0.00$0.00$0.00$115M
Total debt$470K$4.49M$170K$270K$0.00
Net debt-$-5.52M$3.3M-$-4.42M-$-7.99M-$-40K
Cash flow statement
20252024202320222021
Net income-$-11.91M-$-16.52M-$-5.11M-$-3.49M-$-760K
Depreciation and amortization$10K$30K$40K$60K$0.00
Stock-based compensation$130K$5.86M$130K$120K$0.00
Change in working capital$600K-$-1.58M$90K$240K-$-470K
Accounts receivable$0.00$0.00$20K-$-40K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-40K$610K$80K-$-40K$0.00
Net cash provided by operating activities-$-10.82M-$-8.4M-$-4.53M-$-3.33M-$-1.41M
Investments in property, plant and equipment-$-10K-$-20K-$-10K-$-40K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-20K$570K-$-520K$0.00
Common stock issued$16.3M$3.05M$0.00$0.00$118.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.6M$5.1M$520K$2.75M$116.4M
Net change in cash$4.8M-$-3.38M-$-3.66M-$-1.77M-$-10K
Cash at end of period$6.08M$1.27M$4.64M$8.31M$40K
Operating cash flow-$-10.82M-$-8.4M-$-4.53M-$-3.33M-$-1.41M
Capital expenditure-$-10K-$-20K-$-10K-$-40K-$0.00
Free cash flow-$-10.83M-$-8.42M-$-4.54M-$-3.38M-$-1.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Silexion Therapeutics Ltd.

        Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

        CEO
        Ilan Hadar
        Employees
        14
        Beta
        -0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Silexion Therapeutics Ltd. (SLXN)?

        InvestorsCraft does not currently publish an intrinsic value for SLXN. How the IC value is calculated.

        Is SLXN undervalued?

        InvestorsCraft does not publish an undervaluation signal for SLXN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.